Category: Uncategorized

Sep 20 2020

Uncategorized

Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia

by Clinical Editor

No Comments

Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint. The data showed improvement in cognition in …

Sep 20 2020

Uncategorized

Institute of Living research team selected to join international research effort studying schizophrenia in young people

by Clinical Editor

No Comments

A research team at the Institute of Living will join an international research effort studying schizophrenia in high-risk adolescents and young adults. About 3.2% to 7% of young people in...

Sep 20 2020

Uncategorized

NIH public-private partnership to advance early interventions for schizophrenia

by Clinical Editor

No Comments

Effort is part of the Accelerating Medicines Partnership to promote development of effective, targeted treatments.

Sep 19 2020

Uncategorized

Schizophrenia Tx Eases Depression in Bipolar Disorder

by Clinical Editor

No Comments

An atypical antipsychotic approved to treat schizophrenia improved depressive episodes for patients with bipolar disorder, according to an industry-supported trial. In a group of 333 patients with …

Sep 19 2020

Uncategorized

NIH to promote early intervention for schizophrenia via public-private partnership

by Clinical Editor

No Comments

The National Institutes of Health announced a new public-private partnership, the goal of which is to meet the urgent need for early therapeutic interventions for people at risk of developing...

Sep 19 2020

Uncategorized

NIH public-private partnership to advance early interventions for schizophrenia

by Clinical Editor

No Comments

Effort is part of the Accelerating Medicines Partnership to promote development of effective, targeted treatments.

Sep 19 2020

Uncategorized

Researchers reveal sex differences in association between symptoms of schizophrenia and superoxide dismutase

by Clinical Editor

No Comments

Schizophrenia is a disabling psychiatric disorder characterized by positive symptoms, such as hallucinations and delusions, negative symptoms, such as decreased expression ability, and cognitive …

Sep 19 2020

Uncategorized

Boehringer’s schizophrenia med boosts cognition in phase 2

by Clinical Editor

No Comments

Boehringer Ingelheim’s schizophrenia hopeful hit the mark in a phase 2 study, helping patients overcome cognitive impairment that can affect everyday tasks, such as remembering important dates or …

Sep 18 2020

Uncategorized

Schizophrenia: Nurture cannot overcome nature

by Clinical Editor

No Comments

In the great nature vs. nurture debate, nature just got a win. UCI research led by Amal Alachkar found that too much of a certain amino acid in utero caused...

Sep 18 2020

Uncategorized

NIH public-private partnership to advance early interventions for schizophrenia

by Clinical Editor

No Comments

Effort is part of the Accelerating Medicines Partnership to promote development of effective, targeted treatments.